A Texas-based company, Minicircle, is preparing to offer an injectable gene...

A Texas-based company, Minicircle, is preparing to offer an injectable gene therapy focused on increasing longevity. This new treatment aims to stimulate the production of klotho, a protein linked to anti-aging processes. Minicircle plans to launch the therapy outside the U.S. regulatory framework, specifically in regions such as Honduras, the Bahamas, and Panama. The intention is to bypass comprehensive trials typically required by the FDA and instead operate in locations with less stringent oversight. The company’s approach reflects a trend where biomedical innovation may shift to countries with more flexible regulatory environments if others choose a slower or more cautious path. 📰 @aipost